Prostate Embolization for Benign Prostatic Hyperplasia
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This is a Phase I/II investigator sponsored FDA-approved Investigational Device Exemption
protocol, with the primary goal of determining the safety of prostatic artery embolization
(PAE) for benign prostatic hyperplasia. Our primary goal is to document the frequency of
side effects, particularly bladder and rectal complications, which may occur as a result of
this procedure. Secondarily, the study will provide preliminary data to determine its
effectiveness in diminishing obstructive symptoms associated with BPH.